Multi-Cancer Early Detection with EpiDava
Epimorphic SRL is a biotech developing EpiDava — a multi-cancer early detection assay based on plasma cell-free DNA sequencing.
Genome compartmentalization
Biologically informed compartmentalization of the genome to strengthen early cancer signal resolution.
GC-independent metrics
GC-independent normalization metrics for robust performance across samples and sequencing conditions.
Dispersion-based metrics
Dispersion-based metrics that capture subtle epigenomic signal variability linked to cancer.
Our Team
Radu Niculae
CEO
Software Engineer, R&D in Tech & AI
Leads Epimorphic’s strategy, execution, and clinical collaborations
Vlad Moisoiu, MD, PhD
CSO
MD & dual PhDs in Physics & Cancer Genetics
Fulbright Scholar at Johns Hopkins (Liquid Biopsy & Bioinformatics)
Contact
We're based in Bucharest, Romania, but we're happy to connect with anyone around the world. Use the details below to get in touch.